* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Stroke volume-to-wall stress ratio as a load
Cardiac contractility modulation wikipedia , lookup
Electrocardiography wikipedia , lookup
Heart failure wikipedia , lookup
Echocardiography wikipedia , lookup
Mitral insufficiency wikipedia , lookup
Hypertrophic cardiomyopathy wikipedia , lookup
Quantium Medical Cardiac Output wikipedia , lookup
Arrhythmogenic right ventricular dysplasia wikipedia , lookup
J Appl Physiol 113: 1267–1284, 2012. First published August 23, 2012; doi:10.1152/japplphysiol.00785.2012. Stroke volume-to-wall stress ratio as a load-adjusted and stiffness-adjusted indicator of ventricular systolic performance in chronic loading Elie R. Chemaly,1 Antoine H. Chaanine,1 Susumu Sakata,2 and Roger J. Hajjar1 1 Cardiovascular Research Center, Mount Sinai School of Medicine, New York, New York; and 2Division of Health Science, Graduate School of Kio University, Nara, Japan Submitted 25 June 2012; accepted in final form 21 August 2012 pressure overload; volume overload; stiffness; contractility; wall stress LOAD DEPENDENCE HAS LONG BEEN recognized in crude indicators of cardiac performance, such as stroke volume (SV) and ventricular pressures, based on the Starling principle, leading to the development of characteristic plots of load and crude performance (31, 50). The most popular of such characteristics are the end-systolic pressure-volume (P-V) relationship (ESPVR) and the relationship between stroke work (SW) and end-diastolic volume (EDV), or preload-recruitable SW (PRSW) (31). When fitted linearly, ESPVR is characterized by its slope Ees (end-systolic elastance) and its volume intercept Vo. In the last 3 decades, starting shortly after these indicators were developed, a number of acute and chronic studies have Address for reprint requests and other correspondence: R. J. Hajjar, Professor and Director, Cardiovascular Research Center, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1030, New York, NY, 10029 (e-mail: [email protected]). http://www.jappl.org questioned the ability of these load-adjusted indicators to accurately reflect systolic performance. Baan and Van der Velde (3) have shown in an acute study, that Ees increased in response to increased afterload more than with increased preload, while Sodums et al. (43) observed a leftward shift of the ESPVR intercept (decreased Vo) in response to acutely increased afterload. Another report by Little et al. (31) studied ESPVR, PRSW, and the maximum change in pressure over time (dP/dtmax)-EDV characteristic with acute inotropic and vasoconstrictive interventions and found only ESPVR to be afterload dependent, through a leftward shift. More recently, Blaudszun and Morel (5) performed an acute study of P-V analysis in rats treated with several positive and negative inotropes, vasoconstrictors, and vasodilators and suggested that Ees was afterload dependent and did not reflect inotropy, as opposed to its intercept Vo. Van den Bergh et al. (50) acutely studied the inotropic response and response to changes in preload and afterload of several load-adjusted indicators in normal mice and concluded PRSW to be the most useful indicator, based on inotropic response and load dependence. Another limitation of these indicators was shown in a relatively recent report from Aghajani et al. (2). They studied ESPVR and PRSW in large-animal models of acute heart failure from various causes and found Ees to be increased in acute heart failure, reflecting the preload dependence of the failing hearts and thus contradicting the reduced systolic function; PRSW responded variably in these experiments (2). Ees measures left ventricular (LV) systolic performance (7, 10), as well as ventricular stiffness. The increase of Ees in processes affecting ventricular stiffness is well recognized in recent and less recent reports. Two such processes (7) are aging (14) and hypertension (8). In human hypertensive heart disease, Borlaug et al. (8) have recently shown that increases in arterial elastance (Ea) were matched by increases in Ees with preserved Ees-to-Ea ratio (Ees/Ea) and coupling. The increase in Ees was maintained in hypertensive patients with heart failure and preserved LV ejection fraction (LVEF), while other indicators showed reduced contractility (8). Thus a complex interplay between ventricular systolic stiffness and afterload confounds the relationship between ventricular contractility and Ees, in acute and chronic settings. In addition, Zile et al. (52) showed a lack of response to the ex vivo maximum systolic elastance of the LV to ischemia-reperfusion when ischemia-reperfusion also led to an increase in LV end-diastolic pressure (LVEDP). Altogether, the findings by Zile et al. (52) and others (8) demonstrate a significant interference of LV passive stiffness and afterload in the value of Ees to assess LV contractility. Other known load-independent variables, such as PRSW, may also remain elevated, or at least not lowered, in pres- 8750-7587/12 Copyright © 2012 the American Physiological Society 1267 Downloaded from http://jap.physiology.org/ by 10.220.33.1 on May 4, 2017 Chemaly ER, Chaanine AH, Sakata S, Hajjar RJ. Stroke volume-to-wall stress ratio as a load-adjusted and stiffness-adjusted indicator of ventricular systolic performance in chronic loading. J Appl Physiol 113: 1267–1284, 2012. First published August 23, 2012; doi:10.1152/japplphysiol.00785.2012.—Loadadjusted measures of left ventricle (LV) systolic performance are limited by dependence on LV stiffness and afterload. To our knowledge, no stiffness-adjusted and afterload-adjusted indicator was tested in models of pressure (POH) and volume overload hypertrophy (VOH). We hypothesized that wall stress reflects changes in loading, incorporating chamber stiffness and afterload; therefore, stroke volume-to-wall stress ratio more accurately reflects systolic performance. We used rat models of POH (ascending aortic banding) and VOH (aorto-cava shunt). Animals underwent echocardiography and pressure-volume analysis at baseline and dobutamine challenge. We achieved extreme bidirectional alterations in LV systolic performance, end-systolic elastance (Ees), passive stiffness, and arterial elastance (Ea). In POH with LV dilatation and failure, some load-independent indicators of systolic performance remained elevated compared with controls, while some others failed to decrease with wide variability. In VOH, most, but not all indicators, including LV ejection fraction, were significantly reduced compared with controls, despite hyperdynamic circulation, lack of heart failure, and preserved contractile reserve. We related systolic performance to Ees adjusted for Ea and LV passive stiffness in multivariate models. Calculated residual Ees was not reduced in POH with heart failure and was reduced in VOH, while it positively correlated to dobutamine dose. Conversely, stroke volume-to-wall stress ratio was normal in compensated POH, markedly decreased in POH with heart failure, and, in contrast with LV ejection fraction, normal in VOH. Our results support stroke volumeto-wall stress ratio as a load-adjusted and stiffness-adjusted indicator of systolic function in models of POH and VOH. 1268 Ventricular Stiffness and Performance in Chronic Loading sure overload-induced LV systolic dysfunction, as shown recently (12). We took a systematic approach to test two major hypotheses. 1) The first hypothesis is as follows. Most classical indicators of load-independent systolic performance are affected by acute and chronic changes of LV stiffness and afterload. This effect precludes their use as indicators of LV systolic performance when LV stiffness and afterload either increase or decrease in chronic loading. Therefore, a load-adjusted and stiffness-adjusted indicator is needed. 2) The second hypothesis is as follows. The ratio of SV to wall stress (SV/wall stress) can serve as a load-adjusted and stiffness-adjusted indicator of LV systolic performance. To test our hypotheses, we varied LV systolic performance, along with Ees, Ea, and LV passive stiffness over a wide range in rat models of pressure-overload hypertrophy (POH) and volume-overload hypertrophy (VOH), and measured baseline and postdobutamine LV function and stiffness. Animal Use and Care All animals were obtained and handled, as approved by the Institutional Animal Care and Use Committee of the Mount Sinai School of Medicine, in accordance with the “Principles of Laboratory Animal Care by the National Society for Medical research and the Guide for the Care and Use of Laboratory Animals” (National Institutes of Health Publication no. 86 –23, revised 1996). Animal models used and their time points are shown in Table 1. Surgical Model of Pressure-Overload-Induced LV Hypertrophy and Failure by Ascending Aortic Banding The surgical procedure was previously described (33). Male Sprague-Dawley rats (body weight 70 –100 g) underwent ascending aortic constriction under general anesthesia (ketamine up to 85 mg/kg and xylazine up to 10 mg/kg, intraperitoneally). The chest was shaved, and animals were intubated and mechanically ventilated. The chest area was scrubbed and opened intercostally on the right side within 1 cm of the axilla to access the ascending aorta. The ascending aorta was identified and separated from the superior vena cava by blunt dissection. A Weck hemoclip (Teflex medical) stainless-steel clip of ⬃1 mm of adjusted diameter was placed around the ascending aorta. The chest was closed in three layers, and animals were allowed to recover. Sham-operated animals underwent the same procedure without aortic constriction. Normal animals were virgin male Sprague-Dawley rats purchased at an approximate age of 6 mo and an approximate body weight of 500 g. Surgical Model of Volume-Overload-Induced LV Hypertrophy by Aorta-Cava Fistula The surgical procedure was described elsewhere (49). Male Sprague-Dawley rats (body weight 250 –300 g) underwent aorta-cava fistula creation under general anesthesia (ketamine up to 85 mg/kg and xylazine up to 10 mg/kg, intraperitoneally). The abdominal area was shaved, and animals were intubated and mechanically ventilated. Chemaly ER et al. Ventral laparotomy was performed. The aorta and inferior vena cava (IVC) were exposed between the renal arteries and the iliac bifurcation. Both vessels were temporarily occluded at two sites, proximal and distal to the intended shunt site, with a Bulldog clip. An 18GA angiocath was inserted over a needle into the exposed free wall of the abdominal aorta and advanced through the connective tissue fascia separating the aorta and the IVC. Several back-and-forth insertions and withdrawals of the angiocath were performed across the two vessels through the same hole to ensure the presence of a significant shunt. After the needle and the angiocath were withdrawn, the ventral aortic puncture site was sealed with a drop of cyanoacrylate. Successful shunt could be confirmed by pulsatile flow of oxygenated blood into the vena cava from the aorta. Laparotomy was closed in two layers, and animals were allowed to recover. In sham animals, the laparotomy was performed without functional shunt. Echocardiographic and Morphometric Assessment of LV Geometry and Function Echocardiography was performed at designated time points under sedation by intraperitoneal ketamine up to 80 mg/kg, with starting doses as low as 10 mg given to diseased rats and supplemented by additional injections until optimal sedation was obtained. Sedation was optimized by giving the lowest dose of ketamine needed to 1) restrain the animal and prevent motion artifact, and 2) maintain the heart rate in the range of 350 – 450 beats/min. Ketamine was chosen based on our laboratory’s previous experience (12–14) and considering that alternative agents had either a long duration of action (pentobarbital), potentially unsafe for heart failure animals, or a bradycardic effect (isoflurane, xylazine), as demonstrated elsewhere (44). Moreover, ketamine is recommended in murine echocardiography based on a favorable comparison against ketamine/xylazine (51). The chest was shaved. Short-axis parasternal two-dimensional views of the LV at the midpapillary level and long-axis parasternal views of the LV were obtained using a GE Vivid echocardiography apparatus with a 13- to 14-MHz linear array probe (General Electric, New York, NY). M-mode measurements of the size of the LV walls and cavities were obtained by two-dimensional guidance from the short-axis view of the LV, as recommended by the American Society of Echocardiography (29). Volumes of the LV cavity in end-diastole and end-systole were calculated using an area-length formula, where the LV is assumed to be bullet-shaped, as previously recommended and described (13, 23, 29). LV EDV and end-systolic volume (ESV) were thus calculated as follows: V ⫽ 5/6 ⫻ A ⫻ L, where V is the volume of the LV cavity in ml, A is the cross-sectional area of the LV cavity in cm2 obtained from a parasternal short-axis image at the midpapillary level, and L is the length of the LV cavity measured as the distance from the endocardial LV apex to the mitral-aortic junction on the parasternal long-axis image, as previously described (13, 23). Morphometric analysis consisted in separately weighing the left and right ventricles (RV) at the time of death. Animal Selection and Group Assignment Based on Echocardiographic Analysis in Pressure Overload Echocardiography performed at 2 mo after aortic constriction distinguished animals with either compensated concentric LV hypertrophy (CLVH) or dilated cardiomyopathy (DCM). Table 1. Time points of postoperative data collection for the animal models used in the study Group Surgery Pressure overload hypertrophy Mild pressure overload hypertrophy Volume overload hypertrophy 3 mo Ascending aortic banding Ascending aortic banding Aorta-caval shunt Intermediate Echocardiography Time (data not shown) 2, 3 mo 2–4 mo 1 wk/1 mo on selected animals J Appl Physiol • doi:10.1152/japplphysiol.00785.2012 • www.jappl.org Terminal Echocardiography and Hemodynamics Time 4 mo 6 mo 3 mo Downloaded from http://jap.physiology.org/ by 10.220.33.1 on May 4, 2017 METHODS • Ventricular Stiffness and Performance in Chronic Loading Based on the observation that a subset of rats with POH undergo LV dilatation, with end-diastolic dimensions reaching or exceeding the numbers observed with volume-overload rats, we developed criteria for DCM in rats after pressure overload. The three proposed criteria of LV measurement are EDV ⬎ 750 l, ESV ⬎ 200 l, and LVEF ⬍ 70%. At least two, and usually three, of the criteria must be met, with echocardiography performed on ketamine conscious sedation with a heart rate of 350 to 450 beats/min. Animals with confirmed DCM received an echocardiography at 3 and 4 mo and were killed thereafter. Animals with CLVH at 2 mo received an additional echocardiography at 4 mo and were killed if still in CLVH or followed for 2 additional mo if they had transitioned to DCM. At the beginning of the study, longer time frames were used based on previous reports (42, 45). Rats in CLVH at 4 mo were followed until 6 mo and made an additional separate group (CLVH 6 mo, mild POH) that was found to have milder POH. • Integrating Ees and Vo in One Parameter To further integrate simultaneous changes in Ees and Vo, we used an approach similar to Crottogini et al. (17). We sought to combine changes in Ees and changes in Vo in one variable. Knowing that either an increase in Ees or a decrease in Vo will increase the area inside the triangle delimited by ESPVR, the horizontal (volume) axis and a vertical line passing through a reference volume (Vr) were used to compare different conditions. The area under this triangle is an integration of ESPVR (Fig. 1): Vr Integrated共ESPVR,Vo, Vr兲 ⫽ Rats were anesthetized with inhaled 5% (volume/volume) isoflurane for induction, intubated, and mechanically ventilated. Isoflurane was chosen based on our experience (12, 13), on existing methodological recommendations (37), and considering the possibility of dosing adjustment. Isoflurane was progressively lowered to 1.5–2% (volume/volume) for surgical incisions. The chest was opened through a median sternotomy. A 1.9F rat P-V catheter (Scisense, London, Ontario, Canada) was inserted into the LV apex through an apical stab performed with a 25GA needle. Hemodynamic recordings were performed after 5 min of stable heart rate. Isoflurane was maintained at 0.75–1% for adequate anesthesia and a stable heart rate in the range of 300 –350 beats/min. Hemodynamics were recorded subsequently through a Scisense Advantage P-V Control Unit (FY897B). The intrathoracic IVC was transiently occluded to vary venous return during the recording to obtain load-adjusted P-V relationships (see Fig. 5, RESULTS). Linear fits were obtained for ESPVR, PRSW, and the end-diastolic P-V relationships (EDPVR). Fifty microliters of 30% NaCl were slowly injected into the external jugular vein for ventricular parallel conductance measurement, as previously described (37). Blood volume was obtained as blood conductance and calibrated based on Baan’s equation (4) using the baseline SV by conductance and matching it with the SV obtained by echocardiography, as previously described (37). In all P-V tracings, the end-systolic pressure (ESP) and ESV were determined at the end of the systolic ejection phase. (2) Using a linear ESPVR fit, Eqs. 1 and 2 are combined Ees Integrated共ESPVR,Vo, Vr兲 ⫽ 2 ⫻ 共Vr2 ⫺ V2o兲 ⫺ Ees ⫻ Vo ⫻ 共Vr ⫺ Vo兲 (3) Other P-V Loop Parameters The Ea was calculated as the ratio of ESP to SV. SW (in mmHg ⫻ l) was obtained from the area of the P-V loop representing LV ejection. PRSW (in mmHg) is the slope of SW vs. EDV (l) when EDV is varied by IVC occlusion (37). Meridional LV wall stress was calculated as reported by Grossman et al. (22) as ⫽ PR 2h共1 ⫹ h ⁄ 2R兲 (4) where P is LV pressure, R is LV cavity radius, and h is LV wall thickness, measured at corresponding points of the cardiac cycle (end-systole or end-diastole). Dobutamine Challenge During P-V Loop Acquisition Dobutamine was infused through the external jugular vein, first at 8 g/min for 1–2 min for priming, then at 1, 2, 4, and 8 g/min. Infusion was maintained for 5 min at each level before P-V loop data Pressures at Equal Volumes From the Linear ESPVR It is recognized that either an increase in Ees or a decrease in Vo leads to a shifting of ESPVR to higher pressures at equal volumes (10). Thus, to align different animals on the same volumes, and calculate ESP at equal ESV, as previously reported (13), we used the linear ESPVR equation: ESP ⫽ Ees ⫻ 共ESV ⫺ Vo兲 (1) Fig. 1. Integrating the end-systolic pressure (ESP)-volume (ESV) relationship between the volume intercept Vo and a reference volume Vr, based on Crottogini et al.(17). J Appl Physiol • doi:10.1152/japplphysiol.00785.2012 • www.jappl.org Downloaded from http://jap.physiology.org/ by 10.220.33.1 on May 4, 2017 Invasive Hemodynamic Measurements by P-V Loops 兰 ESP ⫻ d共ESV兲 Vo Animal Selection and Group Assignment Based on Echocardiographic Analysis in Volume Overload Successful patent aorta-cava shunt was determined by an enddiastolic LV diameter by M-mode echocardiography of at least 8 mm, and usually more than 9 mm in the same conditions of sedation described above, at echocardiography completed 1 mo after surgery. Moreover, all animals with patent fistulas had continuous and turbulent shunt flow measured by pulse-wave and color-flow Doppler ultrasound, in addition to a distinct palpable abdominal thrill. The fistula itself was thus detected as early as 1 wk after surgery. Animals were analyzed 3 mo postshunt (Table 1). 1269 Chemaly ER et al. 1270 Ventricular Stiffness and Performance in Chronic Loading collection. In normal or sham-operated rats, the full infusion protocol was often not completed due to a very low ESV achieved on dobutamine, interfering with the measurement catheter, as previously reported (50). Statistical Analysis RESULTS Ventricular Hypertrophy and Dysfunction by Echocardiographic and Morphometric Analysis Echocardiographic and morphometric characteristics are shown in Table 2. In POH, LV wall thickness increased significantly, with concentric hypertrophy in CLVH and LV dilatation (significant increases in EDV and ESV) with decreased LVEF in heart failure (DCM group). Interestingly, LV wall thickness was significantly lower in the DCM group than in their CLVH counterpart (Table 2, top). In all POH, LV mass increased significantly, with a further increase in LV/body weight in DCM vs. CLVH counterpart (Table 2, top), while in DCM, RV mass was also increased, reflecting POH of the RV from increased LV filling pressures (Tables 2, top, and 3, top). Similarly, a mild increase in RV mass did reach statistical significance in severe POH with CLVH vs. normal (uncorrected P value); however, the RV weight-to-body weight ratio did not differ (Table 2, top); this finding is also in line with a milder increase in LV filling pressures in CLVH (Table 3, top). Mild POH animals had significantly lower EDV and ESV and significantly higher LVEF than did sham counterparts (Table 2, middle). VOH was eccentric (significant increases in EDV and ESV), with significant increase in SV and reduction in LVEF and increased LV and RV masses, reflecting biventricular volume overload (Table 2). Comparable LV mass was reached with POH (either CLVH or DCM, Table 2, top) and VOH (Table 2, bottom). Chemaly ER et al. Body Weight Body weights of different animal groups are presented in Table 2. DCM animals had a significantly lower body weight than sham counterparts, reflecting clinical heart failure (Table 2, top). The higher body weight in CLVH vs. normal animals in Table 2, top, is design related (see METHODS). Body weight was also significantly lower in the group of mild POH followed for 6 mo compared with sham (Table 2, middle); the explanation of this finding is less clear since long-term aortic constriction can impact animal growth, and slower growth may improve tolerance to chronic constriction. Volume overload rats 3 mo after aorta-caval fistula had a significantly higher body weight than sham (Table 2, bottom); this may reflect extracellular fluid retention. Baseline Heart Rate by Echocardiography and Invasive Hemodynamics Heart rate measured during echocardiography was significantly lower in DCM compared with CLVH and control animals (11% relative change, Table 2, top). Heart rate during invasive hemodynamic measurements was significantly lower in DCM compared with normal animals (11% relative change, Table 3, top), and in shunt 3-mo animals compared with sham 3-mo counterparts (9% relative change, Table 3, bottom). Baseline Steady-State LV Pressure Patterns Baseline (without dobutamine challenge) steady-state (no IVC occlusion) hemodynamics are shown in Table 3. Significant increases in LV maximal pressure were observed in all POH animals, with comparable increase between CLVH and DCM in severe POH (Table 3, top). In the mild POH-CLVH group, maximal LV pressure shown in Table 3, middle, was also significantly lower than in CLVH and DCM from severe POH (Table 3, top). LV ESP was significantly increased compared with sham in severe, but not mild, POH (Table 3, top and middle). LVEDP was significantly increased in DCM, compared with controls and CLVH (Table 3, top). CLVH showed a milder elevation of LVEDP, which was significant compared with normal rats (uncorrected P ⬍ 0.002, Table 3, top). The LV dP/dtmax differed between POH and controls (P ⫽ 0.037 by ANOVA in Table 3, top, highest in CLVH and lowest in sham), likely reflecting the preload and afterload dependence of LV dP/dtmax (26, 32). The constant of isovolumic relaxation was highest in the DCM group of POH, indicating impaired relaxation (Table 3, top, P ⫽ 0.002 by ANOVA). Effect of Dobutamine on Steady-State Hemodynamics Reveals Differential Response Between Models Animals from all groups were subjected to increasing rates of dobutamine infusions (see METHODS). Figures 2– 4 show the dobutamine dose-response of basic hemodynamic parameters. LV peak pressure was either reduced or unchanged by dobutamine, reflecting concurrent vasodilator and positive inotropic effects (Fig. 2). Dobutamine-associated reductions in maximal LV pressure were mostly seen in control animals (Fig. 2). The effect of dobutamine on LV maximal pressure was variable between control groups (Fig. 2), likely reflecting differences in baseline vascular resistance, endothelial function, age, and anes- J Appl Physiol • doi:10.1152/japplphysiol.00785.2012 • www.jappl.org Downloaded from http://jap.physiology.org/ by 10.220.33.1 on May 4, 2017 Continuous variables were compared by ANOVA, followed by post hoc pairwise comparisons using Student’s t-test with Bonferroni correction for multiple testing. The statistical power of the Bonferroni test is reduced when the number of comparisons increases; therefore, experimental animals were compared with their own controls within substudies to avoid irrelevant comparisons. Considering the important risk of type 2 error related to the Bonferroni correction (38), we provided all of the Bonferroni-corrected P values and, in addition, the uncorrected P values when those were significant. Multivariate ANOVA was used in selected comparisons. A multiple repeated-measurement ANOVA was used for dobutamine dose-response measurements, with an interaction term between dobutamine dose and animal group. The P values after repeatedmeasurement ANOVA were reported after corrections for lack of sphericity, using the Huynh-Feldt correction. Simple and multiple linear regression was used, when indicated. A P value of 0.05 was set as a threshold for significance. Graphic representation of data in box plots shows the median value flanked by the 25th and 75th percentiles as edges of the box, with bars representing the adjacent values to the 25th and 75th percentiles, and dots representing additional outlying values. Statistical analysis used the Stata version 10.1 software (Stata, College Station, TX). • 620 57 27 0.005 560 62 13 406 44 26 0.43 417 35 13 407 31 8 0.96 408 47 6 ESV, l SV, l EF, % LV Anteroseptum (Diastole), mm 448 81 11 465 66 8 0.36 0.57 1.00 466 100 19 1.00 413 91 14 1.00 1.00 87.04 4.50 11 81.68 6.23 8 ⬍0.001 ⬍0.001 ⬍0.001 53.47 14.96 19 ⬍0.001 86.07 7.03 14 1.00 1.00 2.1 0.2 11 2.1 0.2 8 ⬍0.001 0.001 ⬍0.001 2.8 0.3 19 ⬍0.001 3.2 0.4 14 ⬍0.001 ⬍0.001 1117 288 26 ⬍0.001 455 72 12 465 99 8 0.02 615 110 7 400 82 8 0.08 480 81 7 86.33 3.57 8 0.001 78.23 3.23 7 348 131 26 ⬍0.001 69 23 12 769 193 26 ⬍0.001 386 58 12 69.19 6.46 26 ⬍0.001 85.02 3.65 12 Volume-overload hypertrophy 3 mo 64 25 8 0.001 135 34 7 2.1 0.2 26 0.99 2.1 0.2 13 3.4 0.4 8 ⬍0.001 2.2 0.1 7 Mild pressure overload hypertrophy (aortic banding 6 mo) 68 31 11 107 43 8 ⬍0.001 ⬍0.001 ⬍0.001 ⬍0.001 ⬍0.001 516 101 11 572 85 8 ⬍0.001 440 224 19 ⬍0.001 72 51 14 1.00 1.00 906 209 19 ⬍0.001 484 120 14 1.00 1.00 Pressure overload hypertrophy (aortic banding 4 mo) EDV, l 3.40 0.45 19 ⬍0.001 0.007 ⬍0.001 2.09 0.13 11 1.80 0.16 8 ⬍0.001 2.81 0.35 8 ⬍0.001 1.72 0.14 8 2.90 0.42 21 ⬍0.001 1.82 0.21 9 0.20 ⬍0.001 1.08 0.08 11 1.15 0.12 8 ⬍0.001 1.61 0.29 8 0.001 1.14 0.10 8 1.81 0.32 21 ⬍0.001 1.05 0.07 9 2.99 0.35 14 ⬍0.001 ⬍0.001 LVW/BW, mg/g 1.87 0.22 19 ⬍0.001 1.73 0.18 14 ⬍0.001 ⬍0.001 LV Mass, g 0.50 0.10 21 ⬍0.001 0.27 0.03 9 0.28 0.10 8 0.85 0.29 0.03 8 0.79 0.13 21 ⬍0.001 0.46 0.06 9 0.49 0.17 8 0.31 0.44 0.04 8 0.48 0.07 11 0.45 0.08 8 ⬍0.001 ⬍0.001 ⬍0.001 ⬍0.001 ⬍0.001 0.25 0.03 11 0.28 0.03 8 ⬍0.001 0.97 0.15 19 ⬍0.001 0.53 0.16 14 0.85 1.00 RVW/BW, mg/g 0.31 0.08 14 1.00 0.19 (0.034 uncorrected) 0.53 0.08 19 ⬍0.001 RV Mass, g n, No. of animals. EDV, end-diastolic volume; ESV, end-systolic volume; SV, stroke volume; EF, ejection fraction; LV, left ventricle; LVW/BW, mg/g: ratio of LV weight in mg over body weight in g; RV, right ventricle; RVW/BW, mg/g: ratio of RV weight in mg over body weight in g; CLVH, compensated-concentric left ventricular hypertrophy; DCM, dilated cardiomyopathy; ANOVA, analysis of variance. Sham-3 mo Mean SD n P vs. sham Mean SD n 572 44 8 0.001 662 47 8 367 46 19 0.36 (0.026 uncorrected) 0.03 0.12 (0.047 uncorrected) 399 32 11 412 46 8 0.017 413 50 14 1.00 1.00 Heart Rate, beats/min Chemaly ER et al. Downloaded from http://jap.physiology.org/ by 10.220.33.1 on May 4, 2017 J Appl Physiol • doi:10.1152/japplphysiol.00785.2012 • www.jappl.org Shunt-3 mo Mean SD n P vs. sham Mean SD n Mean SD n Mean SD n P for ANOVA 521 54 11 644 109 8 0.001 1.00 1.00 P vs. CLVH P vs. normal Mean SD n P vs. sham 583 49 14 0.19 0.10 (0.007 uncorrected) 553 47 19 0.01 Body Weight, g Mean SD n P vs. sham P vs. normal Parameter • Sham-6 mo CLVH Sham-4 mo Normal DCM CLVH Group Table 2. Echocardiographic and morphometric analysis of animal models used in the study Ventricular Stiffness and Performance in Chronic Loading 1271 1272 Ventricular Stiffness and Performance in Chronic Loading • Chemaly ER et al. Table 3. Baseline invasive hemodynamic analysis of animal models used in the study Group Parameter LV Maximal Pressure, mmHg LV End-diastolic Pressure, mmHg LV End-systolic Pressure, mmHg LV Maximal dP/dt, mmHg/s of Isovolumic LV Relaxation (Weiss) Heart Rate, beats/min 10.35 2.53 7 1.00 342 19 7 1.00 1.00 1.00 Pressure overload hypertrophy (aortic banding 4 mo) CLVH DCM 245 26 7 ⬍0.001 13 4 7 1.00 P vs. normal ⬍0.001 Mean SD n P vs. sham 261 29 17 ⬍0.001 0.30 (0.002 uncorrected) 27 7 17 ⬍0.001 177 26 17 ⬍0.001 0.84 ⬍0.001 1.00 ⬍0.001 140 10 8 133 8 5 ⬍0.0001 ⬍0.001 7 2 8 9 1 5 ⬍0.0001 ⬍0.001 132 13 8 122 13 5 ⬍0.0001 P vs. CLVH Normal Sham-4 mo P vs. normal Mean SD n Mean SD n P for ANOVA 166 29 7 0.017 0.045 9758 1095 7 0.07 (0.004 uncorrected) 0.26 (0.006 uncorrected) 9199 1719 17 0.19 1.00 0.76 8304 590 8 7680 667 5 0.037 12.45 2.05 17 0.13 (0.028 uncorrected) 0.10 (0.044 uncorrected) 0.002 9.29 0.85 8 10.18 1.00 5 0.002 317 33 17 1.00 0.36 0.019 356 21 8 330 34 5 0.020 Mild pressure overload hypertrophy (aortic banding 6 mo) CLVH Sham-6 mo Mean SD n P vs. sham Mean SD n 199 8 4 0.002 130 25 4 Mean SD n P vs. sham Mean SD n 128 8 14 0.14 134 9 5 12 8 4 0.15 5 1 4 149 12 4 0.15 120 34 4 8555 678 4 0.30 7621 1500 4 9.24 0.57 4 0.42 8.95 0.36 4 355 37 4 0.43 334 32 4 8535 705 14 0.97 8547 471 5 10.39 1.75 14 0.16 9.13 1.31 5 348 32 14 0.042 381 18 5 Volume-overload hypertrophy 3 mo Shunt-3 mo Sham-3 mo 9 3 14 0.10 7 2 5 111 17 14 0.08 126 9 5 n, No. of animals. dP/dt, change in pressure over time; , time constant. thesia-related effects. dP/dtmax increased in response to dobutamine, with significantly impaired response in POH (Fig. 3A), preserved response in mild POH (Fig. 3B), and preserved to enhanced response in VOH (statistically significant group-dose interaction, Fig. 3C). Stroke volume response to dobutamine was significantly reduced in POH and mild POH (Fig. 4, A and B) and preserved in VOH (Fig. 4C). P-V Loops During IVC Occlusion The baseline Vo intercept of ESPVR was significantly higher in DCM after POH, with P ⬍ 0.0001 by ANOVA and P ⱕ 0.001 for DCM compared with normal, sham counterparts and CLVH counterparts (Table 4, top). The baseline Vo intercept did not differ significantly from control animals in other disease groups (Table 4). POH was associated with a significant increase in the slope of EDPVR (Fig. 7A). Serial P-V loops after IVC occlusion are shown in Fig. 5, in representative POH and VOH animals. Dobutamine Challenge: Effect on Ees, Ea, and EDPVR Baseline Ees, Ea, Vo, Ees/Ea, and EDPVR in POH and VOH In responsive animals, dobutamine marginally increased Ees (Fig. 8, B and C), despite a major and significant decrease in Ea (Fig. 8), resulting in large and significant increases in the Ees/Ea with an “uncoupling” of the Ees-Ea coupling observed at baseline (Fig. 8). The response of Ea and Ees/Ea was significantly reduced in all disease models, except mild POH (Fig. 8). Dobutamine did not lead to appreciable changes in EDPVR (data not shown). Baseline (without dobutamine challenge) Ees, Ea, Ees/Ea, and EDPVR were obtained during IVC occlusion. Baseline Ees and Ea were the highest in POH and the lowest at 3 mo of VOH (Fig. 6). Baseline Ees/Ea was not significantly affected by POH and significantly reduced in VOH (Fig. 6). J Appl Physiol • doi:10.1152/japplphysiol.00785.2012 • www.jappl.org Downloaded from http://jap.physiology.org/ by 10.220.33.1 on May 4, 2017 Mean SD n P vs. sham Ventricular Stiffness and Performance in Chronic Loading • Chemaly ER et al. 1273 Fig. 2. Box plots of maximal left ventricular (LV) pressure on dobutamine in animal models of pressure overload hypertrophy (POH) and volume overload hypertrophy (VOH). LV maximal pressure is stable or reduced by dobutamine infusion in control animals. Dobutamine is infused at 0, 1, 2, 4, and 8 g/ min. P values for repeated-measurement ANOVA indicate level of significance for group (G), dobutamine dose (D), and group-dose (GD) interaction; P values are omitted for nonsignificant results. A: POH. P ⬍ 0.0001 for G, P ⫽ 0.045 for D (Huynh-Feldt correction). B: mild POH. P ⫽ 0.0001 for G. C: VOH 3 mo. P ⫽ 0.0043 for G, P ⫽ 0.01 for D (Huynh-Feldt correction), P ⫽ 0.005 for GD interaction (Huynh-Feldt correction). CLVH, compensated-concentric LV hypertrophy; DCM, dilated cardiomyopathy. In all figures, *P ⬍ 0.05, **P ⱕ 0.01, ***P ⱕ 0.001, ****P ⱕ 0.0001. The pertinence of these findings in load-adjusted indicators of systolic performance to our main hypothesis is further discussed. Table 4 presents baseline values of three load-adjusted indicators of LV systolic performance: PRSW, ESP at a reference ESV of 800 l by conductance (based on Eq. 1), and the ESPVR integrated between Vo and 800 l (based on Eqs. 2 and 3). All three indicators showed high variability in diseased groups and were significantly and consistently elevated in CLVH animals compared with controls (Table 4, top and middle). DCM animals had consistently lower values than CLVH animals (Table 4, top) for all three parameters. PRSW was higher in DCM than controls (Table 4, top, significant uncorrected P values). ESP measured at an ESV of 800 l by conductance was lower in DCM than controls, but this difference did not reach statistical significance (Table 4, top). The integrated ESPVR from Vo to 800 l by conductance was significantly lower in DCM than in controls (Table 4, top). In contrast, VOH animals had lower ESP at an ESV of 800 l by conductance than sham counterparts; however, they did not differ from controls by the two other indicators, PRSW and integrated ESPVR from Vo to 800 l by conductance (Table 4, bottom). Residual Ees Adjusted on Ea and EDPVR and Its Connection to Systolic Performance To address the confounding effect of Ea and EDPVR on the relationship between Ees and systolic performance, we calculated a residual value of Ees after adjusting for Ea and EDPVR in multivariate analysis. We tested the hypothesis that 1) a reduction in residual Ees would identify systolic failure in DCM animals; and 2) residual Ees would, conversely, be relatively preserved in VOH animals showing no heart failure, mostly preserved response to dobutamine and simultaneous reductions of Ees, Ea, and EDPVR. Baseline Ees as a function of Ea and EDPVR. As shown in Figs. 6 and 7, we have varied Ea from 0.07 to 0.54 mmHg/l and EDPVR from 0 to 0.13 mmHg/l in our chronic loading models, resulting in Ees varying from 0.04 to 0.93 mmHg/l. This severalfold variation of all three parameters allows us to measure statistical interactions and infer potential mechanical interactions. At baseline, and across models, Ees was linearly and significantly correlated to Ea (Fig. 9A) and to the slope of EDPVR (Fig. 9B). Fig. 3. Box plots of LV dP/dt max on dobutamine in animal models of POH and VOH. Maximal dP/dt increased in response to dobutamine, with impaired response in POH, preserved response in mild POH, and enhanced response in VOH. A: POH. P ⫽ 0.003 for G, P ⬍ 0.0001 for D (Huynh-Feldt correction), P ⫽ 0.0006 for GD interactions (Huynh-Feldt correction). B: mild POH. P ⫽ 0.01 for G, P ⫽ 0.004 for D (Huynh-Feldt correction). C: VOH 3 mo. P ⬍ 0.0001 for D (Huynh-Feldt correction), P ⫽ 0.037 for GD interaction (Huynh-Feldt correction). P values are for repeated-measurements ANOVA. J Appl Physiol • doi:10.1152/japplphysiol.00785.2012 • www.jappl.org Downloaded from http://jap.physiology.org/ by 10.220.33.1 on May 4, 2017 Other Load-Adjusted Indicators of LV Systolic Performance at Baseline Are Variably Dependent on LV Afterload and Stiffness 1274 Ventricular Stiffness and Performance in Chronic Loading • Chemaly ER et al. Fig. 4. Box plots of stroke volume (SV) (by conductance) on dobutamine in animal models of POH and VOH. SV response to dobutamine is blunted in POH groups, reduced in mild POH, and preserved to marginally enhanced in VOH. A: POH. P ⬍ 0.0001 for G, P ⬍ 0.0001 for D and GD interaction (Huynh-Feldt correction). B: mild POH. P ⫽ 0.0004 for G, P ⫽ 0.0003 for D (Huynh-Feldt correction), P ⫽ 0.016 for GD interaction (Huynh-Feldt correction). C: VOH 3 mo. P ⬍ 0.0001 for G, P ⬍ 0.0001 for D (Huynh-Feldt correction), P ⫽ 0.065 for GD interaction (uncorrected). P values are for repeated-measurements ANOVA. Ees ⫽ 0.62Ea ⫹ 2.0EDPVR ⫹ 0.0046 (5) where R2 ⫽ 0.44 for the model, P ⫽ 0.002 for Ea, and P ⫽ 0.011 for EDPVR; the intercept did not differ significantly from zero (P ⫽ 0.92). Thus, when both Ea and LV passive stiffness are varied chronically over a wide range, they independently and positively influence LV Ees. Residual Ees in the assessment of LV systolic performance at baseline in DCM animals after pressure overload. Based on the statistically independent correlation of Ees to Ea and EDPVR, we sought to determine the residual variation of Ees in models of variable (severe or marginal) systolic impairment after adjusting for Ea and EDPVR. We assessed the ability of residual Ees to reflect systolic dysfunction independently from afterload and passive stiffness. We compared n ⫽ 27 control (normal and sham-operated) animals to n ⫽ 17 animals with DCM after POH, considering that these animals had impaired LV systolic performance: LV dilatation in face of POH, decreased LVEF, and heart failure (Tables 2 and 3). In univariate analysis, Ees, Ea, and EDPVR were all significantly higher in DCM than in controls (P ⱕ 0.0001 for Ees and EDPVR, P ⫽ 0.009 for Ea). To calculate the difference in residual Ees after adjustment on Ea and EDPVR between DCM and control animals, we used a multiple-linear regression with Ees as a dependent variable, shown in Table 5. Residual Ees did not decrease and remained nonsignificantly higher by 0.11 mmHg/l in DCM animals (P ⫽ 0.15, Table 5). Due to the high colinearity between DCM status, Ea, and EDPVR, all independent variables lost their statistical significance in the multivariate model. These results indicate 1) that Ees is highly constrained by LV stiffening in POH, even POH associated with overt LV systolic failure; and 2) that, in POH with heart failure, residual Ees is not decreased along with decreased systolic performance. Residual Ees in the assessment of LV systolic performance at baseline in chronic volume overload. Animals with chronic aorta-caval shunt (3 mo) had lower LVEF, lower Ees, and lower Ea than sham counterparts. However, their filling pressures did not indicate heart failure, and dobutamine challenge showed relatively maintained contractile reserve, in contrast to the similarly dilated POH-DCM animals. Using the approach outlined in Table 5, we determined the residual change in Ees associated with aorta-caval shunt at 3 mo (n ⫽ 14 animals) compared with n ⫽ 27 control animals. As opposed to DCM in POH, Ees, Ea, and EDPVR were all decreased in shunt animals at 3 mo compared with controls (P ⬍ 0.0001 for Ees and Ea, P ⫽ 0.003 for EDPVR). However, the residual Ees associated with volume overload, adjusted for Ea and EDPVR, was significantly reduced by 0.06 mmHg/l in shunt animals compared with controls (P ⫽ 0.02, Table 6). Residual effect of dobutamine, DCM, and VOH on Ees after adjustment on Ea and EDPVR. To better understand the interconnection between Ees, Ea, and EDPVR in relationship with dobutamine dose as a measure of inotropy, the multivariate analyses performed in Tables 5 and 6 were extended to include Ees adjusted on Ea and EDPVR, dobutamine dose, systolic dysfunction of variable severity from pressure or volume overload (disease model variable), and the interaction between dobutamine dose and disease model. The goal was to assess the ability of the afterload-adjusted and complianceadjusted Ees to respond to the simultaneous inotrope-vasodilator dobutamine and to distinguish the response in overt heart failure animals (DCM group) or animals with subtle (or no) systolic dysfunction (shunt 3 mo group) from the response in controls. The multivariate linear regressions are reported in Tables 7 and 8. Ees, adjusted on Ea and the EDPVR slope, remained higher than control in DCM and lower than control in shunt. The adjusted Ees increased independently and significantly with dobutamine dose, and, using a disease-dose interaction term, we show a significant blunting of the dobutamine dose response to the adjusted Ees in both disease models (Tables 7 and 8). This result indicates that the residual Ees, although related to inotropy, does not reliably distinguish the otherwise differ- J Appl Physiol • doi:10.1152/japplphysiol.00785.2012 • www.jappl.org Downloaded from http://jap.physiology.org/ by 10.220.33.1 on May 4, 2017 Importantly, the slope of the regression line of Ees vs. Ea was close to unity, and the intercept of the regression line did not differ significantly from zero (Fig. 9A), indicating wellpreserved coupling of Ees and Ea across models of chronic ventricular loading. To test the independent correlation of EDPVR and Ea to Ees, we used a multiple linear regression, leading to equation (5) Ventricular Stiffness and Performance in Chronic Loading • Chemaly ER et al. 1275 DISCUSSION Fig. 5. Pressure-volume (P-V) loops after inferior vena cava (IVC) occlusion in representative pressure and volume overload animals. A: pressure overload animals, with normal (middle loops), CLVH (left loops), and DCM (right loops). B: volume overload animals, with sham (left loops) and VOH (right loops). ent inotropic reserve of POH-DCM (blunted) and VOH (preserved), as shown using other indicators (Figs. 3 and 4). SV/Wall Stress As an Alternative Indicator of Systolic Performance That Corrects for Ventricular Load and Stiffness We sought to explain whether the reduced LVEF and the reduced residual Ees represented truly reduced systolic performance or a feature of remodeling in the otherwise hyperdynamic (high SV, see Table 2) shunt model. We were also interested in explaining the intriguing increase in ESV and end-systolic dimensions in the rat aorta-cava shunt model, shown by us and others (24), considering that increased ESV is not consistent with diastolic volume overload, nor is it consistent with a low-resistance hyperdynamic circulation (primarily leading to an increased SV and, logically, to a lower ESV). To that end, we hypothesized that the increased SV required by the aorta-cava shunt necessitated an increase in loading throughout the cardiac cycle, according to the Starling principle (28). We used LV end-diastolic and end-systolic wall stress as loading indicators (20) and hypothesized that the high required wall stress would lead to a higher ESV in a more Our systematic study addresses the chronic afterload and stiffness dependence of load-adjusted indicators of LV systolic function using rat models of chronic ventricular loading and proposes load-adjusted and stiffness-adjusted indicators. LV systolic performance, afterload, and stiffness were varied in a bidirectional way over a broad interval using rat models of pressure and volume overload. Acutely, we used dobutamine challenge, with distinct inotropic and vasodilator activity. First, we demonstrate quantitatively the limitations of common and less common load-adjusted indicators of LV systolic performance, by showing their greater dependence on LV stiffness and afterload over systolic performance. The latter was previously shown for Ees in situations of high LV stiffness, such as hypertension (8) and aging (14); we demonstrate it in the highly compliant ventricles of VOH, where systolic performance is relatively preserved when assessed comprehensively, and some of the studied indicators markedly reduced. The comprehensive assessment of systolic failure in the DCM group takes into account the occurrence of heart failure, LV dilatation in the face of pressure overload, and the loss of contractile reserve. To our knowledge, this is the first study to combine POH, with or without systolic dysfunction and dilatation, together with VOH, to study the interplay of chronic changes in LV stiffness, afterload, and LV systolic performance. Second, we propose SV/wall stress as a load-adjusted and stiffness-adjusted indicator of LV systolic performance, and, in our study, this indicator appears to outperform classical loadadjusted indicators of LV systolic performance. Previous studies used adjusted indicators, taking into account the slope and intercept of several characteristics (31), mainly correcting Ees for its intercept Vo (10, 31). We used classical adjustments of the linearly fitted ESPVR, combining Ees and Vo, either as pressure at equal volume (13), or by integration (17), or using the Ees/Ea (11). Our more advanced J Appl Physiol • doi:10.1152/japplphysiol.00785.2012 • www.jappl.org Downloaded from http://jap.physiology.org/ by 10.220.33.1 on May 4, 2017 compliant ventricle facing a low afterload (and a low ESP) and facing a significantly lower ESP at equal ESV compared with controls (Table 4, bottom). In an approach similar to Gaasch et al. (20), who measured changes in LV shortening vs. wall stress, we used the SV/wall stress as another measurement of load-adjusted systolic performance (Fig. 10). End-systolic and end-diastolic wall stress were significantly increased in dilated animals (DCM and shunt groups) compared with controls, while end-diastolic wall stress was normal in CLVH animals from severe POH (Table 9); end-systolic wall stress was lower in CLVH vs. normal (uncorrected P value, Table 9, top). In the mild POH group as well, end-systolic wall stress was significantly lower than in sham animals (Table 9, middle). DCM animals had a significantly reduced ratio of SV over enddiastolic and end-systolic wall stress compared with CLVH and controls, with a statistically significant difference between groups by multivariate ANOVA combining both parameters as dependent variables (Fig. 10A). In contrast, these ratios were similar to control values in CLVH and shunt animals, indicating that the increase in ESV in shunt animals is most likely adaptive, translates into a higher wall stress that is required to achieve a higher SV based on the Starling principle, and does not represent systolic failure. 1276 Ventricular Stiffness and Performance in Chronic Loading • Chemaly ER et al. residual Ees accounts for Ea and passive stiffness (two statistically independent physical determinants of Ees) through multiple linear regression. We thoroughly demonstrate the limitations of these approaches in commonly used rat models of POH and VOH. Baan and Van der Velde (3) have shown that Ees increased in response to acutely increased afterload, while Sodums et al. (43) observed a leftward shift of the ESPVR intercept (decreased Vo) in response to acutely increased afterload. In our POH (chronically increased afterload) animals with CLVH, Vo was not significantly decreased (Table 4, top and middle), while Ees was significantly increased in mild longterm POH, but not with CLVH, after 4 mo of more severe POH (Fig. 6, A and B); however, in partial agreement with both reports (3; 43), and with Little et al. (31), CLVH animals had higher than normal values of indicators combining Ees and Vo (Table 4, top and middle). Thus, taking together our study and previous reports, chronic and acute increases in afterload may indeed lead to a left shift of ESPVR, whether it is by increased Ees, reduced Vo, or both (3, 31, 43). In POH complicated by overt systolic failure (DCM), Vo was shifted to the right (Table 4, top), but Ees was significantly higher than that in sham animals (Fig. 6A), leading to combined indicators that varied widely (Table 4, top). As shown in Table 4, top, ESP measured at an ESV of 800 l by conductance was significantly lower in DCM than CLVH, thus correctly measuring decompensation within POH, and its point estimate was lower than that of control counterparts, although this difference failed to reach statistical significance (Table 4, top). The integrated ESPVR from Vo to 800 l by conductance was significantly lower in DCM than in CLVH and controls (Table 4, top), adequately reflecting systolic failure in that setting. Regarding PRSW, the acute study by Little et al. (31) found this parameter to be afterload independent, and the acute study by Van den Bergh et al. (50) concluded that PRSW was the preferred indicator in mice based on its sensitivity to inotropy and its load independence. Moreover, in the chronic study by Borlaug et al. (8) on hypertensive patients with heart failure and preserved LVEF, Ees was increased, but PRSW was significantly lower than that of controls. In contrast with these J Appl Physiol • doi:10.1152/japplphysiol.00785.2012 • www.jappl.org Downloaded from http://jap.physiology.org/ by 10.220.33.1 on May 4, 2017 Fig. 6. Box plots of baseline end-systolic elastance (Ees), arterial elastance (Ea), and Ees-to-Ea ratio (Ees/Ea) in animal models of pressure and volume overload. At baseline, Ees and Ea were variably increased in POH and decreased in VOH. Ees/Ea is preserved in POH and reduced in chronic VOH. A: POH. Ees: P ⫽ 0.016 by ANOVA, P ⫽ 0.048 for DCM vs. sham 4 mo. Ea: P ⫽ 0.003 by ANOVA, P ⫽ 0.02 for DCM vs. sham 4 mo, P ⫽ 0.042 for DCM vs. normal, P ⫽ 0.03 for CLVH vs. sham 4 mo. Ees/Ea: P ⫽ 0.13 by ANOVA. B: mild POH. Ees: P ⫽ 0.006, Ea: P ⫽ 0.026, Ees/Ea: P ⫽ 0.21. C: VOH 3 mo. Ees: P ⬍ 0.0001, Ea: P ⬍ 0.0001, Ees/Ea: P ⫽ 0.025. Ventricular Stiffness and Performance in Chronic Loading • 1277 Chemaly ER et al. Table 4. Other load-adjusted indicators of left ventricular systolic function in animal models used in the study Group Parameter PRSW, mmHg Vo of ESPVR, l ESP at 800 l, mmHg Integrated ESPVR from Vo to 800 l, mmHg ⫻ l Pressure overload hypertrophy (aortic banding 4 mo) CLVH Mean SD n P vs. sham P vs. normal DCM Mean SD n P vs. sham P vs. CLVH P vs. normal Normal 194 92 17 0.41 (0.0055 uncorrected) 0.02 0.34 (0.0022 uncorrected) 78 31 8 62 28 5 0.0005 570 429 17 0.001 353 88 5 0.045 0.08 (0.001 uncorrected) 93 141 17 1.00 ⬍0.001 ⬍0.001 ⬍0.001 0.30 ⫺119 178 8 ⫺196 303 5 ⬍0.0001 189 52 8 156 24 5 0.0006 190765 66400 5 ⬍0.001 ⬍0.001 35626 31992 17 0.16 (0.01 uncorrected) ⬍0.001 0.02 85391 23282 8 78733 30502 5 ⬍0.0001 Mild pressure overload hypertrophy (aortic banding 6 mo) CLVH Sham-6 mo Mean SD n P vs. sham Mean SD n 161 63 4 0.047 71 34 4 ⫺172 25 4 0.71 ⫺217 225 4 347 95 4 0.01 143 70 4 168439 46010 4 0.049 77763 57281 4 92 73 14 0.005 221 91 5 71205 54691 14 0.38 96448 49124 5 Volume overload hypertrophy 3 mo Shunt-3 mo Sham-3 mo Mean SD n P vs. sham Mean SD n 62 27 13 0.25 78 20 5 ⫺299 845 14 0.49 ⫺23 221 5 n, No. of animals. ESP, end-systolic pressure; ESPVR, end-systolic pressure volume relationship; Vo, volume intercept of ESPVR; PRSW, preload recruitable stroke work. reports, we show, in our chronic POH study, PRSW to be supranormal in CLVH and failing to decrease in rats with DCM, with even a higher point estimate compared with control counterparts (Table 4, top). Thus an important potential drawback of the classical loadadjusted indicators of LV systolic performance evaluated in Table 4 is their consistently supranormal values in the compensated POH animals (Table 4, top and middle), known to Fig. 7. Box plots of baseline end-diastolic P-V relationships (EDPVR) slope in animal models of pressure and volume overload. At baseline, the slope of EDVR was increased in POH. A: POH. P ⬍ 0.0001 for ANOVA, P ⬍ 0.001 for CLVH vs. sham and normal, P ⫽ 0.004 for DCM vs. sham, and P ⫽ 0.001 for DCM vs. normal. B: mild POH. P ⫽ 0.08. C: VOH 3 mo. P ⫽ 0.27. J Appl Physiol • doi:10.1152/japplphysiol.00785.2012 • www.jappl.org Downloaded from http://jap.physiology.org/ by 10.220.33.1 on May 4, 2017 Sham-4 mo Mean SD n Mean SD n P for ANOVA ⫺288 261 5 1.00 1.00 420 330 5 0.002 0.001 1278 Ventricular Stiffness and Performance in Chronic Loading • Chemaly ER et al. have normal or reduced cellular function (16), with normal or reduced ex vivo function (42). They appear, however, to fall adequately in DCM facing POH, although they do so with notable variability (Table 4, top). This further indicates their stiffness dependence and afterload dependence, as opposed to SV/wall stress ratios, which remain normal in CLVH and reduced in DCM, in agreement with cellular function in the setting of POH, with or without heart failure (16). The indicators studied in Table 4 were either normal or reduced in VOH (Table 4, bottom), and this is further discussed. We consider LVEF to be the simplest of the preloadadjusted indicators of LV systolic performance (26). LVEF correctly reflected systolic dysfunction in POH with DCM. However, in mild POH animals with CLVH followed for 6 mo, LVEF was significantly higher than in sham counterparts, likely from LV geometry changes. As mentioned above, in previous studies, these animals have normal or reduced cellular function (16), with normal or reduced ex vivo function (42). The lower end-systolic wall stress in these animals (Table 9, middle) adds to the complex hemodynamics of this phenotype. By its milder pressure overload (Table 3, middle), this group of animals resembles low gradient human aortic valve stenosis; low flow could not be ascertained, since SV was not significantly lower than sham (Table 2, middle). Adda et al. (1) studied patients with severe aortic stenosis and either low flow (low SV), low gradient, or both and demonstrated a normal LVEF, with significantly smaller LV size for some patients, despite impaired systolic function by ventricular strain imaging, suggesting that LVEF overestimated systolic performance. By contrast, SV/wall stress was normal in these animals (Fig. 10B). In addition, we believe this is the first study to question the validity of low LVEF as an indication of systolic dysfunction in our low-afterload model of VOH. It is recognized that LVEF is afterload dependent (6, 26), and LVEF is known to increase with Ees and decrease with Ea (27). LVEF is expected to J Appl Physiol • doi:10.1152/japplphysiol.00785.2012 • www.jappl.org Downloaded from http://jap.physiology.org/ by 10.220.33.1 on May 4, 2017 Fig. 8. Box plots of Ees, Ea, and Ees/Ea on dobutamine in animal models of pressure and volume overload. Ees responded variably to dobutamine, while a consistent decrease in Ea was measured, leading to an increase in Ees/Ea in responsive animals. The response of Ees/Ea to dobutamine was blunted or reduced in almost all disease models. A: POH. Ees: P ⬍ 0.0001 for G, P ⫽ 0.055 for GD interactions (uncorrected). Ea: P ⬍ 0.0001 for G, P ⬍ 0.0001 for D (Huynh-Feldt correction), P ⬍ 0.0001 for GD interactions (Huynh-Feldt correction). Ees/Ea: P ⬍ 0.0001 for G, P ⫽ 0.01 for D (Huynh-Feldt correction), P ⫽ 0.0017 for GD interactions (Huynh-Feldt correction). B: mild POH. Ees: P ⫽ 0.032 for D (uncorrected). Ea: P ⫽ 0.041 for D (Huynh-Feldt correction). Ees/Ea: P ⫽ 0.044 for D (Huynh-Feldt correction). C: VOH 3 mo. Ees: P ⬍ 0.0001 for G, P ⫽ 0.0498 for D (Huynh-Feldt correction), P ⫽ 0.046 for GD interactions (Huynh-Feldt correction). Ea: P ⬍ 0.0001 for G, P ⬍ 0.0001 for D (Huynh-Feldt correction), P ⫽ 0.029 for GD interactions (Huynh-Feldt correction). Ees/Ea: P ⬍ 0.0001 for G, P ⫽ 0.0003 for D (Huynh-Feldt correction), P ⫽ 0.005 for GD interactions (Huynh-Feldt correction). P values are for repeated-measurements ANOVA. Ventricular Stiffness and Performance in Chronic Loading • 1279 Chemaly ER et al. Table 6. Residual Ees associated with volume overload by aorta-cava shunt at 3 mo after adjusting for Ea and EDPVR Parameter EDPVR Ea Shunt (shunt ⫽ 1 if aorta cava shunt at 3 mo, shunt ⫽ 0 if control) Intercept Regression Coefficient P Value 0.14 ⫾ 1.2 0.39 ⫾ 0.12 0.91 0.003 ⫺0.06 ⫾ 0.03 0.09 ⫾ 0.04 0.02 0.036 Values are means ⫾ SE; N ⫽ 41 observations. Dependent variable is Ees. Model R2 ⫽ 0.57. increase or remain normal in chronic volume overload until more advanced pathological stages: in clinical mitral regurgitation, LVEF remains within the normal range, despite significant muscle dysfunction (6). In aortic regurgitation, postoperative recovery is impaired once LVEF falls below normal (6). Thus the well-demonstrated early and significant reductions in Table 5. Residual Ees associated with DCM after adjusting for Ea and EDPVR Parameter Regression Coefficient P Value EDPVR Ea DCM (DCM ⫽ 1 if DCM, DCM ⫽ 0 if control) Intercept 1.61 ⫾ 1.70 0.54 ⫾ 0.28 0.35 0.06 0.11 ⫾ 0.07 0.02 ⫾ 0.08 0.15 0.81 Values are means ⫾ SE; N ⫽ 44 observations. Dependent variable is end-systolic elastance (Ees). Model R2 ⫽ 0.41. Ea, arterial elastance; EDPVR, slope of the LV end-diastolic pressure-volume relationship. Table 7. Differential dose response of Ees adjusted on Ea and EDPVR to dobutamine in DCM (pressure-overload induced heart failure) and control animals Parameter Regression Coefficient P Value EDPVR Ea DCM (DCM ⫽ 1 if DCM, DCM ⫽ 0 if control) Dobutamine dose DCM-dobutamine interaction Intercept 0.91 ⫾ 0.56 0.53 ⫾ 0.13 0.11 ⬍0.001 0.13 ⫾ 0.042 0.029 ⫾ 0.0082 ⫺0.035 ⫾ 0.010 0.034 ⫾ 0.042 0.003 0.001 0.001 0.41 Values are means ⫾ SE; N ⫽ 150 observations. Dependent variable is Ees. Model R2 ⫽ 0.34. J Appl Physiol • doi:10.1152/japplphysiol.00785.2012 • www.jappl.org Downloaded from http://jap.physiology.org/ by 10.220.33.1 on May 4, 2017 Fig. 9. Scatter plot of Ees vs. Ea and EDPVR slope at baseline in animal models of pressure and volume overload. Ees was significantly correlated to Ea (A) and to the slope of EDPVR (B) at baseline. LVEF in the low afterload aorta-cava shunt model, with demonstrated reversibility of cardiac remodeling (24) and preserved cellular shortening (41), are surprising in light of what is known about LVEF in volume-overload valvular diseases. Importantly, these animals did not develop heart failure in our study and maintained dobutamine response by most indicators (Figs. 3 and 4), except Ees/Ea (Fig. 8) and residual Ees (Table 8). Moreover, the high ESV observed by us and others in this model is incompatible with a hyperdynamic circulation with low afterload, and, unlike high EDV, high ESV does not purely reflect volume overload. Knowing that dilatation in these models is necessary to increase the SV (6), we hypothesized that the required increase in loading necessitated increases in wall stress throughout the cardiac cycle and not just at end-diastole. Considering the very compliant ventricle facing a low afterload, with lower ESP at equal ESV (Table 4, bottom), an increase in ESV, leading to a lower LVEF, may be needed to achieve the required wall stress. In confirmation of our hypothesis, the SV/wall stress was preserved in shunt animals (Fig. 10C), contradicting the low LVEF. Therefore, our results suggest a distinct compliance dependence and a distinct pattern of “reverse afterload dependence” of LVEF in this model of VOH. Taken together with the normal SV/wall stress, the findings in Table 4, bottom, of normal PRSW and integrated ESPVR support normal systolic function in VOH, and the reduced ESP at equal ESV (to the same point estimate as DCM) more likely represents the low afterload and high compliance of this VOH model (Table 4, bottom). The primary hemodynamic findings in the models used in our study are consistent with previous reports of rat models of POH (36) and VOH (24), although other studies have shown reduced PRSW in chronic aorta-cava shunt in rats (24). Our dobutamine response in normal and sham rats with respect to Ees and Ea is similar to previous data on piglets (11). Moreover, Blaudszun and Morel (5) recently studied the ef- 1280 Ventricular Stiffness and Performance in Chronic Loading Table 8. Differential dose-response of Ees adjusted on Ea and EDPVR to dobutamine in aorta-cava shunt animals (volume-overload hypertrophy, 3 mo) and control animals Parameter Regression Coefficient EDPVR Ea shunt (shunt ⫽ 1 if shunt, shunt ⫽ 0 if control) Dobutamine dose Shunt-dobutamine interaction Intercept ⫺0.36 ⫾ 1.15 0.40 ⫾ 0.12 ⫺0.070 ⫾ 0.028 0.025 ⫾ 0.0056 ⫺0.020 ⫾ 0.0070 0.088 ⫾ 0.035 P Value 0.76 0.001 0.014 ⬍0.001 0.005 0.015 Values are means ⫾ SE; N ⫽ 120 observations. Dependent variable is Ees. Model R2 ⫽ 0.46. Chemaly ER et al. ESPVR in rats after a single injection of 1 mg/kg of dobutamine (46). In contrast with our study, ESPVR was obtained by increasing the afterload through a gradual occlusion of the ascending aorta (46). They observed a shifting to the left of the linear ESPVR, with an increased slope (46). This latter study stresses the importance of the afterload in assessing the effects of dobutamine (46). More recently, Connelly et al. (15) studied the ESPVR of rats by IVC occlusion immediately after a single 4 g/kg intravenous bolus of dobutamine. They found an increase in the slope of the ESPVR; however, the ESP at steady state was increased by 25 mmHg, suggesting a hypertensive response to the bolus (15). Using dobutamine infusions, like in our study and the study by Blaudszun and Morel (5), instead of boluses may also explain differences between studies through a different vasodilator-inotrope balance. In other species, the study by Crottogini et al. (17) on dogs reports a left shift of ESPVR on dobutamine, together with an increase in peak LV pressure; similarly, Gayat et al. (21) recently reported the dobutamine response of ESPVR recorded noninvasively in healthy human volunteers and found an increase in Ees, a stable Ea, and an increase in systolic pressure. Importantly, we show the dobutamine response of all indicators to be reduced in DCM and compensated severe POH and preserved in mild POH and in VOH. Fig. 10. Box plots of SV-to-wall stress ratios (SV/wall stress) in animal models of pressure and volume overload. In contrast with the load-adjusted indicators, the SV/wall stress was normal in all compensated models of POH and VOH and markedly reduced in DCM (see text). A: POH. SV/end-diastolic wall stress: P ⬍ 0.0001 for ANOVA, DCM lower than all (P ⬍ 0.001). SV/end-systolic wall stress: P ⫽ 0.030 for ANOVA, DCM lower than CLVH (P ⫽ 0.02); P ⬍ 0.001 for DCM vs. normal and sham if Bonferroni correction does not include CLVH. P ⬍ 0.0001 for Wilks’ lambda by multivariate ANOVA (MANOVA). B: mild POH. SV/end-diastolic wall stress: P ⫽ 0.79. SV/end-systolic wall stress: P ⫽ 0.19. P ⫽ 0.37 for Wilks’ lambda by MANOVA. C: VOH 3 mo. SV/end-diastolic wall stress: P ⫽ 0.24. SV/end-systolic wall stress: P ⫽ 0.92. P ⫽ 0.50 for Wilks’ lambda by MANOVA. J Appl Physiol • doi:10.1152/japplphysiol.00785.2012 • www.jappl.org Downloaded from http://jap.physiology.org/ by 10.220.33.1 on May 4, 2017 fects of dobutamine infusion at progressive rates in rats and found no increase in Ees. The dobutamine effect we observe is dominated by a reduction in Ea, with a relatively stable Ees, resulting in an increase in Ees/Ea (Fig. 8). This most likely reflects opposing effects of increased inotropy and decreased afterload on Ees in our study and serves as additional evidence of the partial afterload dependence of Ees. We were surprised by the significant vasodilator effect of dobutamine in our hands, ascertained by the response of LV maximal pressure to dobutamine as either decreased or unchanged in normal animals, despite an evident inotropic effect (increased dP/dtmax; Figs. 2 and 3). Tachibana et al. studied the shift of the • Ventricular Stiffness and Performance in Chronic Loading Table 9. End-diastolic and end-systolic wall stress Group Parameter End-diastolic Wall Stress, mmHg Pressure overload hypertrophy Mean SD n P vs. sham P vs. normal CLVH DCM Normal Sham-4 mo (aortic banding 4 mo) 4.78 6.78 1.63 4.21 7 7 1.00 1.00 1.00 1.00 (0.029 uncorrected) 16.82 42.56 5.55 17.42 17 17 ⬍0.001 ⬍0.001 ⬍0.001 ⬍0.001 ⬍0.001 ⬍0.001 4.90 11.91 1.22 3.92 8 8 5.59 10.81 0.80 3.32 5 5 ⬍0.0001 ⬍0.0001 Mild pressure overload hypertrophy (aortic banding 6 mo) CLVH Sham-6 mo Mean SD n P vs. sham Mean SD n 3.15 1.33 4 0.33 4.00 0.88 4 4.98 3.42 4 0.043 10.01 1.95 4 Volume-overload hypertrophy 3 mo Shunt-3 mo Sham-3 mo Mean SD n P vs. sham Mean SD n 9.48 5.14 14 0.046 4.38 1.53 5 22.68 8.99 14 0.014 11.38 1.41 5 n, No. of animals. Limitations and Future Directions Our study has specific conceptual and practical limitations. We studied multiple models of cardiac hypertrophy and failure and aimed for experimental conditions to be as consistent as possible. As mentioned earlier, we were able to achieve comparable levels of LV hypertrophy between POH and VOH, along with comparable levels of LV maximal pressure between POH-CLVH and POH-DCM. Nonetheless, we still found significantly lower heart rates in DCM and shunt 3-mo animals than in other groups in Tables 2 and 3. These findings are most likely related to different cardiac effects of sedation between groups. The nonfailing rats, whether CLVH or sham/normal rats, have, in our experience, a narrow therapeutic index with either ketamine or isoflurane; thus increasing anesthetic dose to reduce the heart rate of these animals by an 11% relative value would have been challenging. In Table 3, the heart rate was significantly lower in shunt 3-mo compared with sham 3-mo animals during invasive hemodynamic recording (P ⫽ 0.042). However, the heart rate of the shunt 3-mo group was comparable to the heart rate of the other control groups in Table 3, while the heart rate of the sham 3-mo group was higher, indicating, in this latter case, a lower sensitivity of this partic- Chemaly ER et al. 1281 ular group of healthy rats to the anesthetic. The potential consequences of these differences in heart rate are threefold. First, the reduced heart rate under sedation/anesthesia may be a surrogate for hemodynamic depression by the sedative, as shown in mice (51). However, this 11% reduced heart rate is unlikely to account for the doubling of EDV and the severalfold increase in ESV, as well as the profoundly reduced ejection fraction in the DCM group by echocardiography (Table 2). Second, heart rate can affect contractility through the force-frequency relationship (Bowditch effect). In normal ventricular myocardium, including rat myocardium, the forcefrequency relationship is positive (9, 19), although a negative or triphasic force-frequency relationship was observed in normal rat myocardium (34). One study evaluated the positive force-frequency relationship of rat myocardium within the physiological heart rate of 6 – 8 Hz (30). In that study, relative changes of ⬍20% in the tension of rat RV trabeculae were measured with 1-Hz change in stimulation frequency (30). However, since the force-frequency relationship is reversed in failing myocardium, including in rats (9), the rather slight increases in heart rates observed in our study in nonfailing animals (CLVH, controls) and decreases in failing animals (DCM) may have all caused an increase in inotropy. Third, heart rate can affect ventricular filling; however, it is unlikely that the doubled LV volumes in DCM animals are due to the 11% decrease in heart rate compared with CLVH (Table 2, top). Similarly, it is unlikely that the major increase in LVEDP of DCM animals is due to this relative bradycardia (Table 3, top). As we noted, this increase in LVEDP is corroborated by RV hypertrophy in DCM animals (Table 2, top). Another limitation is our use of a linear fit for the ESPVR and the EDPVR characteristics, known to be curvilinear in rodents when constructed in the full range of variation of LV volume (48). However, the in vivo ESPVR and EDPVR are obtained during IVC occlusion over a limited interval within which a linear fit is possible. Based on this consideration, Ees in that range is meaningful, but the intercept Vo is a “virtual” intercept, the mathematical Vo of the in vivo constructed ESPVR characteristic, and not Vo in the sense of the real value of ESV when ESP ⫽ 0, as stated earlier by Tachibana et al. (46). Negative Vo of linear and curvilinear ESPVR obtained in vivo are reported in other species (2). In that case, Vo retains its value as an indicator of the left or right shift of the ESPVR, which is an important characteristic (10). In a direct physiological measure of Vo used by us and others (42, 49), the LV volume is controlled by a balloon inserted in the LV of a nonworking isolated heart with retrograde perfusion; thus unloading the ventricle to a systolic pressure of zero is feasible (unlike IVC occlusion) and does not compromise its coronary perfusion. Tachibana et al. (46) have applied an approach in which they recorded in vivo P-V loops with a conductance catheter and incorporated in the ESPVR a Vo measured postmortem after rigor contracture. However, a major limitation of this procedure is the inclusion of volumes measured by two different methods in the same curve. Once the issue of Vo is considered, choosing a linear as opposed to a curvilinear fit is related to the measured values and their distribution. Indeed, our experiments on ex vivo rat use an exponential fit for ESPVR (42, 48, 49). In that case, the parameters of the exponential curve are dependent on the shape J Appl Physiol • doi:10.1152/japplphysiol.00785.2012 • www.jappl.org Downloaded from http://jap.physiology.org/ by 10.220.33.1 on May 4, 2017 Mean SD n P vs. sham P vs. CLVH P vs. normal Mean SD n Mean SD n P for ANOVA End-systolic Wall Stress, mmHg • 1282 Ventricular Stiffness and Performance in Chronic Loading Chemaly ER et al. Our ability to generalize our results may be limited by the use of “extreme” models: severe POH with massive hypertrophy and ensuing dilatation, and VOH by aorta-caval shunt. Thus our results on POH only partially agree with the conceptually similar, clinical study by Borlaug et al. (8) on Ees. Also, because of differences in afterload and wall stress, conclusions on VOH by aorta-cava shunt need to be applied with caution to the more clinically relevant aortic and mitral regurgitations. However, in these valvular conditions, we can expect SV/wall stress to be a more sensitive and specific breakpoint in the natural history of the disease, and its response to load-modifying medical therapy, than LVEF. In VOH models, initial dilatation reflects volume overload, and decreases in LVEF would await dilatation secondary to ventricular decompensation; in contrast, SV/wall stress incorporates two indexes of decompensation, dilatation and rising filling pressures, and is expected to drop with increases in any of the two. We did calculate a residual Ees, thus measuring a component of ventricular stiffness not attributed to the more passive EDPVR and not transmitted from the afterload Ea. We do show this residual Ees to reflect the acute inotropic effect of dobutamine; however, it is not clear why the adjusted residual Ees does not decrease and may still increases in POH with DCM and decreases in VOH. We are aware of one study measuring cellular stiffness in POH and attributing cellular stiffening to microtubule accumulation; the latter leading to impaired cell shortening (47). Interestingly, this microtubule accumulation does not occur in VOH (16). Conclusion We believe our study to be the first to address the limited value, mainly due to stiffness dependence and afterload dependence, of most load-adjusted parameters of LV systolic performance in chronic POH and VOH alike. We used highstiffness and high-compliance models of POH and VOH and compared them side by side and facing dobutamine challenge. We also show LVEF to be stiffness dependent in VOH. We propose the SV/wall stress as a load-adjusted and stiffness-adjusted indicator of systolic performance. Gaash et al. (20) and others (16) have expressed LV shortening-wall stress relationships. Indeed, changes in LV loading variably combine changes in pressure and changes in dimension. Pressure and dimension “interconvert” through compliance; thus a load measurement using one of the two is compliance dependent. Wall stress, in contrast, is a pressure-dimension product that overcomes this compliance dependence. We show the superiority of this indicator in VOH. In clinical studies of POH and CLVH, low SV and normal LVEF are demonstrated, due to small ventricles (1) and likely normal wall stress; in that setting, SV/wall stress may conversely be more sensitive than LVEF in measuring systolic dysfunction in some forms of POH as well. Measuring SV/wall stress has also attractive therapeutic implications: understanding and preventing the potential loss of forward flow in stiff ventricles subjected to small reductions in filling volumes for the treatment of congestive heart failure, resulting (through stiffness) in larger reductions in filling pressures, leading to underloading by loss of wall stress, and leading to loss of SV. Our proposed indicator also has important physiological significance: SV was preserved between animal groups of J Appl Physiol • doi:10.1152/japplphysiol.00785.2012 • www.jappl.org Downloaded from http://jap.physiology.org/ by 10.220.33.1 on May 4, 2017 of the curve and may not reflect LV systolic function (42). This drawback has led to the use of alternative indicators similar to those used with linear in vivo ESPVR, which are the ESP at a given ESV, or an integration of the ESPVR (42); moreover, the exponential ESVR has been linearized and converted to an equivalent maximal elastance, which is equivalent to Ees (48). Obtaining the ESPVR over a limited volume interval compatible with in vivo measurements makes the integration of the full ESPVR (Figs. 1 and 5) used in Table 4 problematic. We aimed at generalizing the approach of Crottogini et al. (17), who used the area under a linear ESPVR to measure withinanimal changes of systolic performance, within the operating pressure and volume interval of that particular animal, as also done more recently by Blaudszun and Morel (5). The integration approach has the advantage of generating, over a range of ESP and ESV, one numeric value that increases if Ees increases or Vo decreases and appears to correctly delineate systolic failure in DCM animals and shows normal values in VOH animals, with supranormal values in CLVH animals as a drawback (Table 4). Another limitation is the measurement of SV/wall stress. We suggest using the end-diastolic and end-systolic wall stress, but, ideally, more comprehensive parameters integrating the ejected volume to the wall stress throughout the cardiac cycle are needed. In our study, we obtained LV dimensions by echocardiography and subsequent pressure measurements through LV apical stab on open-chest animals. Simultaneous imaging-pressure collection, or sonomicrometry, allowing continuous measurement of LV chamber size and wall thickness, would permit SV/wall stress measurement in occlusion studies and with dobutamine challenge. Pressure sensors can be inserted percutaneously (or more generally through a closed-chest approach), allowing echocardiography to be performed simultaneously with pressure measurements. A SV-wall stress characteristic curve obtained by inferior vena-caval occlusion is expected to provide a range of variation of SV within a range of wall stress, which is more representative than a steady-state single-point estimate. Integrating the curve summarizes that information. The slope (or derivative) of this curve may inform on the load dependence of performance at a cellular level, and future studies are needed to correlate this indicator to cellular stiffness (47). SV and wall stress are potentially obtainable with noninvasive measures. Nevertheless, this is challenging with the currently available technology. LV volumes and wall thickness are classically obtained by imaging. Noninvasive LVESP can, in fact, be measured as the pressure at the dicrotic notch (incisura) of the aortic pressure tracing obtained by carotid aplanation tonometry, as reported recently by Gayat et al. (21). However, the aortic pressure at the incisura may not be an accurate reflection of the LVESP in patients with diseased aortic valves (aortic stenosis and regurgitation); and these patients are precisely the ones in most need of improved systolic function parameters. Regarding noninvasive LVEDP measurement, multiple echocardiographic indicators of LV diastolic function are known to predict LVEDP in a semiquantitative manner, as most recently studied by Rafique et al. (40). To our knowledge, these popular echocardiographic measures do not give a point estimate of the end-diastolic pressure of an individual patient (35). • Ventricular Stiffness and Performance in Chronic Loading POH, indicating its vital and homeostatic role; SV was appropriately increased in the VOH due to shunt flow. Reduction in SV as a result of heart failure would indicate advanced stages. Wall stress is also physiologically relevant as an indicator of loading sensed at the cellular level (18). Finally, although our study demonstrates the usefulness of this index in chronic loading, we are confident that it will also perform well in other surgical models of cardiac dysfunction, under pharmacological challenge, and in transgenic models. In the particular case of ischemic cardiomyopathy following myocardial infarction, reductions in LVEF and Ees are classical (39). However, it is known that the viable myocardium after infarction remodels through VOH (25); the latter process may contribute to the changes seen in classical P-V parameters, and measuring SV/wall stress would more specifically assess systolic decompensation. GRANTS DISCLOSURES No conflicts of interest, financial or otherwise, are declared by the author(s). AUTHOR CONTRIBUTIONS Author contributions: E.R.C., S.S., and R.J.H. conception and design of research; E.R.C. and A.H.C. performed experiments; E.R.C. analyzed data; E.R.C. and R.J.H. interpreted results of experiments; E.R.C. prepared figures; E.R.C. drafted manuscript; E.R.C., A.H.C., and R.J.H. edited and revised manuscript; E.R.C., A.H.C., S.S., and R.J.H. approved final version of manuscript. REFERENCES 1. Adda J, Mielot C, Giorgi R, Cransac F, Zirphile X, Donal E, SportouchDukhan C, Reant P, Laffitte S, Cade S, Le Dolley Y, Thuny F, Touboul N, Lavoute C, Avierinos JF, Lancellotti P, Habib G. Low-flow, lowgradient severe aortic stenosis despite normal ejection fraction is associated with severe left ventricular dysfunction as assessed by speckletracking echocardiography: a multicenter study. Circ Cardiovasc Imaging 5: 27–35, 2012. 2. Aghajani E, Muller S, Kjorstad KE, Korvald C, Nordhaug D, Revhaugand A, Myrmel T. The pressure-volume loop revisited: is the search for a cardiac contractility index a futile cycle? Shock 25: 370 –376, 2006. 3. Baan J, Van der Velde ET. Sensitivity of left ventricular end-systolic pressure-volume relation to type of loading intervention in dogs. Circ Res 62: 1247–1258, 1988. 4. Baan J, van der Velde ET, de Bruin HG, Smeenk GJ, Koops J, van Dijk AD, Temmerman D, Senden J, Buis B. Continuous measurement of left ventricular volume in animals and humans by conductance catheter. Circulation 70: 812–823, 1984. 5. Blaudszun G, Morel DR. Relevance of the volume-axis intercept, V0, compared with the slope of end-systolic pressure-volume relationship in response to large variations in inotropy and afterload in rats. Exp Physiol 96: 1179 –1195, 2011. 6. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM, Shah PM, Shanewise JS. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 52: e1–e142, 2008. Chemaly ER et al. 1283 7. Borlaug BA, Kass DA. Invasive hemodynamic assessment in heart failure. Cardiol Clin 29: 269 –280, 2011. 8. Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 54: 410 –418, 2009. 9. Brooks WW, Bing OH, Litwin SE, Conrad CH, Morgan JP. Effects of treppe and calcium on intracellular calcium and function in the failing heart from the spontaneously hypertensive rat. Hypertension 24: 347–356, 1994. 10. Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol 289: H501–H512, 2005. 11. Cassidy SC, Chan DP, Allen HD. Left ventricular systolic function, arterial elastance, and ventricular-vascular coupling: a developmental study in piglets. Pediatr Res 42: 273–281, 1997. 12. Chaanine AH, Jeong D, Liang L, Chemaly ER, Fish K, Gordon RE, Hajjar RJ. JNK modulates FOXO3a for the expression of the mitochondrial death and mitophagy marker BNIP3 in pathological hypertrophy and in heart failure. Cell Death Dis 3: 265, 2012. 13. Chemaly ER, Hadri L, Zhang S, Kim M, Kohlbrenner E, Sheng J, Liang L, Chen J, PKR, Hajjar RJ, Lebeche D. Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. J Mol Cell Cardiol 51: 144 –155, 2011. 14. Chen CH, Nakayama M, Nevo E, Fetics BJ, Maughan WL, Kass DA. Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol 32: 1221–1227, 1998. 15. Connelly KA, Prior DL, Kelly DJ, Feneley MP, Krum H, Gilbert RE. Load-sensitive measures may overestimate global systolic function in the presence of left ventricular hypertrophy: a comparison with load-insensitive measures. Am J Physiol Heart Circ Physiol 290: H1699 –H1705, 2006. 16. Cooper GI. Cytoskeletal networks and the regulation of cardiac contractility: microtubules, hypertrophy, and cardiac dysfunction. Am J Physiol Heart Circ Physiol 291: H1003–H1014, 2006. 17. Crottogini AJ, Willshaw P, Barra JG, Armentano R, Cabrera Fischer EI, Pichel RH. Inconsistency of the slope and the volume intercept of the end-systolic pressure-volume relationship as individual indexes of inotropic state in conscious dogs: presentation of an index combining both variables. Circulation 76: 1115–1126, 1987. 18. Curtis MW, Russell B. Micromechanical regulation in cardiac myocytes and fibroblasts: implications for tissue remodeling. Pflügers Arch 462: 105–117, 2011. 19. Endoh M. Force-frequency relationship in intact mammalian ventricular myocardium: physiological and pathophysiological relevance. Eur J Pharmacol 500: 73–86, 2004. 20. Gaasch WH, Zile MR, Hoshino PK, Apstein CS, Blaustein AS. Stressshortening relations and myocardial blood flow in compensated and failing canine hearts with pressure-overload hypertrophy. Circulation 79: 872– 883, 1989. 21. Gayat E, Mor-Avi V, Weinert L, Yodwut C, Lang RM. Noninvasive quantification of left ventricular elastance and ventricular-arterial coupling using three-dimensional echocardiography and arterial tonometry. Am J Physiol Heart Circ Physiol 301: H1916 –H1923, 2011. 22. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 56: 56 –64, 1975. 23. Gueret P, Meerbaum S, Zwehl W, Wyatt HL, Davidson RM, Uchiyama T, Corday E. Two-dimensional echocardiographic assessment of left ventricular stroke volume: experimental correlation with thermodilution and cineangiography in normal and ischemic states. Cathet Cardiovasc Diagn 7: 247–258, 1981. 24. Hutchinson KR, Guggilam A, Cismowski MJ, Galantowicz ML, West TA, Stewart JA Jr, Zhang X, Lord KC, Lucchesi PA. Temporal pattern of left ventricular structural and functional remodeling following reversal of volume overload heart failure. J Appl Physiol 111: 1778 –1788, 2011. 25. Hutchinson KR, Stewart JA Jr, Lucchesi PA. Extracellular matrix remodeling during the progression of volume overload-induced heart failure. J Mol Cell Cardiol 48: 564 –569, 2010. 26. Ishikawa K, Chemaly ER, Tilemann L, Fish K, Ladage D, Aguero J, Vahl T, Santos-Gallego C, Kawase Y, Hajjar RJ. Assessing left ventricular systolic dysfunction after myocardial infarction: are ejection J Appl Physiol • doi:10.1152/japplphysiol.00785.2012 • www.jappl.org Downloaded from http://jap.physiology.org/ by 10.220.33.1 on May 4, 2017 This work was supported by Leducq Foundation through the Caerus network and by National Heart, Lung, and Blood Institute Grants R01 HL093183, HL088434, HL071763, HL080498, HL083156, and P20HL100396 (R. J. Hajjar) and NIH-T32-HL007824 (E. R. Chemaly and A. H. Chaanine). • 1284 27. 28. 29. 30. 31. 33. 34. 35. 36. 37. 38. 39. fraction and dP/dtmax complementary or redundant? Am J Physiol Heart Circ Physiol 302: H1423–H1428, 2012. Kass DA, Maughan WL, Guo ZM, Kono A, Sunagawa K, Sagawa K. Comparative influence of load vs. inotropic states on indexes of ventricular contractility: experimental and theoretical analysis based on pressurevolume relationships. Circulation 76: 1422–1436, 1987. Katz AM. Ernest Henry Starling, his predecessors, and the “Law of the Heart”. Circulation 106: 2986 –2992, 2002. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18: 1440 –1463, 2005. Layland J, Kentish JC. Positive force- and [Ca2⫹]i-frequency relationships in rat ventricular trabeculae at physiological frequencies. Am J Physiol Heart Circ Physiol 276: H9 –H18, 1999. Little WC, Cheng CP, Mumma M, Igarashi Y, Vinten-Johansen J, Johnston WE. Comparison of measures of left ventricular contractile performance derived from pressure-volume loops in conscious dogs. Circulation 80: 1378 –1387, 1989. Mason DT. Usefulness and limitations of the rate of rise of intraventricular pressure (dp-dt) in the evaluation of myocardial contractility in man. Am J Cardiol 23: 516 –527, 1969. Miyamoto MI, del Monte F, Schmidt U, DiSalvo TS, Kang ZB, Matsui T, Guerrero JL, Gwathmey JK, Rosenzweig A, Hajjar RJ. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aorticbanded rats in transition to heart failure. Proc Natl Acad Sci U S A 97: 793–798, 2000. Morii I, Kihara Y, Konishi T, Inubushi T, Sasayama S. Mechanism of the negative force-frequency relationship in physiologically intact rat ventricular myocardium–studies by intracellular Ca2⫹ monitor with indo-1 and by 31P-nuclear magnetic resonance spectroscopy. Jpn Circ J 60: 593–603, 1996. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 22: 107–133, 2009. Norton GR, Woodiwiss AJ, Gaasch WH, Mela T, Chung ES, Aurigemma GP, Meyer TE. Heart failure in pressure overload hypertrophy. The relative roles of ventricular remodeling and myocardial dysfunction. J Am Coll Cardiol 39: 664 –671, 2002. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 3: 1422–1434, 2008. Perneger TV. What’s wrong with Bonferroni adjustments. BMJ 316: 1236 –1238, 1998. Prunier F, Pfister O, Hadri L, Liang L, Del Monte F, Liao R, Hajjar RJ. Delayed erythropoietin therapy reduces post-MI cardiac remodeling 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. • Chemaly ER et al. only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 292: H522–H529, 2007. Rafique AM, Phan A, Tehrani F, Biner S, Siegel RJ. Transthoracic echocardiographic parameters in the estimation of pulmonary capillary wedge pressure in patients with present or previous heart failure. Am J Cardiol 110: 689 –694, 2012. Ryan TD, Rothstein EC, Aban I, Tallaj JA, Husain A, Lucchesi PA, Dell’Italia LJ. Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload. J Am Coll Cardiol 49: 811–821, 2007. Sakata S, Lebeche D, Sakata N, Sakata Y, Chemaly ER, Liang LF, Tsuji T, Takewa Y, del Monte F, Peluso R, Zsebo K, Jeong D, Park WJ, Kawase Y, Hajjar RJ. Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J Mol Cell Cardiol 42: 852–861, 2007. Sodums MT, Badke FR, Starling MR, Little WC, O’Rourke RA. Evaluation of left ventricular contractile performance utilizing end-systolic pressure-volume relationships in conscious dogs. Circ Res 54: 731– 739, 1984. Stein AB, Tiwari S, Thomas P, Hunt G, Levent C, Stoddard MF, Tang XL, Bolli R, Dawn B. Effects of anesthesia on echocardiographic assessment of left ventricular structure and function in rats. Basic Res Cardiol 102: 28 –41, 2007. Suckau L, Fechner H, Chemaly E, Krohn S, Hadri L, Kockskamper J, Westermann D, Bisping E, Ly H, Wang X, Kawase Y, Chen J, Liang L, Sipo I, Vetter R, Weger S, Kurreck J, Erdmann V, Tschope C, Pieske B, Lebeche D, Schultheiss HP, Hajjar RJ, Poller WC. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 119: 1241–1252, 2009. Tachibana H, Takaki M, Lee S, Ito H, Yamaguchi H, Suga H. New mechanoenergetic evaluation of left ventricular contractility in in situ rat hearts. Am J Physiol Heart Circ Physiol 272: H2671–H2678, 1997. Tagawa H, Wang N, Narishige T, Ingber DE, Zile MR, Cooper GI. Cytoskeletal mechanics in pressure-overload cardiac hypertrophy. Circ Res 80: 281–289, 1997. Takaki M. Left ventricular mechanoenergetics in small animals. Jpn J Physiol 54: 175–207, 2004. Takewa Y, Chemaly ER, Takaki M, Liang LF, Jin H, Karakikes I, Morel C, Taenaka Y, Tatsumi E, Hajjar RJ. Mechanical work and energetic analysis of eccentric cardiac remodeling in a volume overload heart failure in rats. Am J Physiol Heart Circ Physiol 296: H1117–H1124, 2009. Van den Bergh A, Flameng W, Herijgers P. Parameters of ventricular contractility in mice: influence of load and sensitivity to changes in inotropic state. Pflügers Arch 455: 987–994, 2008. Xu Q, Ming Z, Dart AM, Du XJ. Optimizing dosage of ketamine and xylazine in murine echocardiography. Clin Exp Pharmacol Physiol 34: 499 –507, 2007. Zile MR, Izzi G, Gaasch WH. Left ventricular diastolic dysfunction limits use of maximum systolic elastance as an index of contractile function. Circulation 83: 674 –680, 1991. J Appl Physiol • doi:10.1152/japplphysiol.00785.2012 • www.jappl.org Downloaded from http://jap.physiology.org/ by 10.220.33.1 on May 4, 2017 32. Ventricular Stiffness and Performance in Chronic Loading